CN Bio
PrivateLast Round
Series B
Apr 23, 2024
Total Funding Raised
$11.75M
Company Overview
CN Bio operates in Healthcare & Life Sciences and is based in Cambridge. Its latest recorded funding round was a Grant round in March 2021.
CN Bio is a biotechnology company that develops organ-on-a-chip platforms for drug discovery.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Biotech Equipment, Clinical Trials
Business Model
B2B
Customer Profile
Hardware Sales, Usage-Based SaaS, Services & Consulting, Government Contracts
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
CN Bio Comparables
Compare CN Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Emulate | 91% | |
| TissUse | 88% | |
| InSphero | 86% |
For institutional investors. Book with your work email.
CN Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Apr 23, 2024 | ||||
| Grant | Mar 2, 2021 | ||||
| Series A | Mar 2, 2020 | ||||
| Grant | Oct 11, 2017 | ||||
| Seed | Jul 15, 2009 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
CN Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| CITIC Securities Investment Co., Ltd. | Series A |
| Bayland Capital | Series B |
| Innovate UK | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 31, 2026
Monthly visitors increased 69% MoM, reaching 15.3K.
- Oct 13, 2025
Launched an all-in-one Organ-on-a-chip system.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventOct 1, 2026
Cn Bio announces the scientific program for the inaugural Organ-on-a-chip e-Symposium, which takes place on Dec 2nd and 8th '26 and features four expert-led sessions on organ-on-a-chip technologies.
- receives_financingAug 12, 2026
On Aug 12th '26, Cn Bio receives $243K (£180k) in Innovate UK grant funding, delivered with NC3Rs, to develop human-relevant pharmacokinetic workflows that reduce animal testing in drug development in United Kingdom.
For institutional investors. Book with your work email.
CN Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about CN Bio's valuation, stock price, and market status.
Is CN Bio a public or private company?
CN Bio is a private company.
What is the current stock price of CN Bio?
CN Bio is a private company, so its shares have no public market price. Caplight tracks CN Bio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is CN Bio worth (valuation)?
Valuation information for CN Bio is not publicly available.
Can I buy CN Bio stock?
CN Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was CN Bio's last funding round?
CN Bio's most recent funding round was Series B on April 23, 2024.
Who are the main investors in CN Bio?
Key investors in CN Bio include CITIC Securities Investment Co., Ltd., Bayland Capital, Innovate UK.
Will CN Bio IPO soon?
No public IPO plans have been announced for CN Bio.
How can I track CN Bio secondary market activity?
Caplight tracks bids, offers, and trades in CN Bio's shares on secondary markets.